Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-positive Advanced Melanoma
NCT05135715Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in melanoma, sponsored by RemeGen. Primary endpoint: Objective Remission Rate at 3 years. Started Apr 2022; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05135715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135715.